CA3206106A1 - Methods for ophthalmic delivery of roflumilast - Google Patents
Methods for ophthalmic delivery of roflumilast Download PDFInfo
- Publication number
- CA3206106A1 CA3206106A1 CA3206106A CA3206106A CA3206106A1 CA 3206106 A1 CA3206106 A1 CA 3206106A1 CA 3206106 A CA3206106 A CA 3206106A CA 3206106 A CA3206106 A CA 3206106A CA 3206106 A1 CA3206106 A1 CA 3206106A1
- Authority
- CA
- Canada
- Prior art keywords
- roflumilast
- eye
- cornea
- concentration
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148008P | 2021-02-10 | 2021-02-10 | |
| US63/148,008 | 2021-02-10 | ||
| US202163261404P | 2021-09-20 | 2021-09-20 | |
| US63/261,404 | 2021-09-20 | ||
| PCT/US2022/015942 WO2022173923A1 (en) | 2021-02-10 | 2022-02-10 | Methods for ophthalmic delivery of roflumilast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206106A1 true CA3206106A1 (en) | 2022-08-18 |
Family
ID=82704332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206106A Pending CA3206106A1 (en) | 2021-02-10 | 2022-02-10 | Methods for ophthalmic delivery of roflumilast |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12102622B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291162A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024506384A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022218993A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206106A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304924A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009352A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022173923A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12263160B2 (en) * | 2021-09-22 | 2025-04-01 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| AR130498A1 (es) * | 2022-09-16 | 2024-12-11 | Iolyx Therapeutics Inc | Composiciones farmacéuticas de alta concentración de roflumilast para administración oftálmica |
| AU2024298631A1 (en) * | 2023-07-25 | 2026-02-05 | Iolyx Therapeutics, Inc. | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ290266B6 (cs) | 1993-07-02 | 2002-06-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
| SK122199A3 (en) | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| BR0013793A (pt) * | 1999-09-06 | 2002-05-14 | Ono Pharmaceutical Co | Medicamentos profiláticos e terapêuticos para doenças oftálmicas |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| JP3805203B2 (ja) * | 2001-02-16 | 2006-08-02 | 日本油脂株式会社 | 点眼用水性懸濁製剤およびその製造方法 |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| IL160271A0 (en) | 2001-09-19 | 2004-07-25 | Altana Pharma Ag | Pharmaceutical compositions containing pde4-inhibitors and nsaid |
| US20060084684A1 (en) * | 2002-05-28 | 2006-04-20 | Altana Pharma Ag | Topically applicable pharmaceutical preparation |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| NZ585697A (en) | 2004-08-02 | 2011-12-22 | Univ Virginia Patent Found | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| ES2421916T3 (es) * | 2005-03-16 | 2013-09-06 | Nycomed Gmbh | Forma farmacéutica de sabor enmascarado que contiene roflumilast |
| SI1885336T1 (sl) | 2005-05-10 | 2009-08-31 | Alcon Inc | Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj |
| AU2006244245B2 (en) | 2005-05-10 | 2010-11-18 | Alcon, Inc. | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
| JP2007016024A (ja) * | 2005-06-09 | 2007-01-25 | Santen Pharmaceut Co Ltd | ロフルミラスト点眼液 |
| WO2006132342A1 (ja) * | 2005-06-09 | 2006-12-14 | Santen Pharmaceutical Co., Ltd. | ロフルミラスト点眼液 |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| DK2250161T3 (da) | 2008-01-18 | 2014-01-27 | Atopix Therapeutics Ltd | Forbindelser med CRTH2-antagonistaktivitet |
| CN103508936A (zh) | 2008-08-22 | 2014-01-15 | 赛诺菲-安万特 | 用于制备吲哚苄胺化合物的中间体 |
| MX2012006401A (es) | 2009-12-03 | 2012-07-10 | Lupin Ltd | Proceso para preparar composiciones oftalmicas farmaceuticas. |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| AU2012232658B2 (en) | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| JP6363506B2 (ja) * | 2011-11-15 | 2018-07-25 | アラーガン、インコーポレイテッドAllergan,Incorporated | シクロスポリンa2型の懸濁剤 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| HK1214159A1 (zh) | 2012-11-08 | 2016-07-22 | Rhizen Pharmaceuticals S.A. | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 |
| US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| WO2015132708A1 (en) | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| WO2020081622A1 (en) | 2018-10-16 | 2020-04-23 | Research Triangle Institute | Subcutaneous biodegradable reservoir device |
| EP4061332A4 (en) | 2019-11-24 | 2023-11-29 | Sol-Gel Technologies Ltd. | TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR |
| US12263160B2 (en) * | 2021-09-22 | 2025-04-01 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
-
2022
- 2022-02-10 US US17/668,858 patent/US12102622B2/en active Active
- 2022-02-10 CA CA3206106A patent/CA3206106A1/en active Pending
- 2022-02-10 AU AU2022218993A patent/AU2022218993A1/en active Pending
- 2022-02-10 MX MX2023009352A patent/MX2023009352A/es unknown
- 2022-02-10 IL IL304924A patent/IL304924A/en unknown
- 2022-02-10 JP JP2023548873A patent/JP2024506384A/ja active Pending
- 2022-02-10 EP EP22753325.4A patent/EP4291162A4/en active Pending
- 2022-02-10 WO PCT/US2022/015942 patent/WO2022173923A1/en not_active Ceased
-
2024
- 2024-09-26 US US18/897,425 patent/US20250009724A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL304924A (en) | 2023-10-01 |
| US20220249451A1 (en) | 2022-08-11 |
| WO2022173923A1 (en) | 2022-08-18 |
| JP2024506384A (ja) | 2024-02-13 |
| US20250009724A1 (en) | 2025-01-09 |
| US12102622B2 (en) | 2024-10-01 |
| EP4291162A1 (en) | 2023-12-20 |
| AU2022218993A1 (en) | 2023-08-03 |
| MX2023009352A (es) | 2023-08-16 |
| EP4291162A4 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250009724A1 (en) | Methods for ophthalmic delivery of roflumilast | |
| US12263160B2 (en) | Methods of treating ocular inflammatory diseases | |
| US20250255809A1 (en) | Ophthalmic pharmaceutical compositions of roflumilast | |
| AU2023201678A1 (en) | Methods for the use of 5'-adenosine diphosphate ribose (ADPR) | |
| JP2018076364A (ja) | 新規ヨードフォア組成物および使用方法 | |
| US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
| US20160051526A1 (en) | The Local Treatment of Inflammatory Ophthalmic Disorders | |
| US20250032468A1 (en) | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases | |
| HK40101566A (en) | Methods for ophthalmic delivery of roflumilast | |
| US20250339419A1 (en) | Methods of treating ocular inflammatory diseases | |
| US20260083712A1 (en) | Methods for treating patients with ocular comorbidities of an autoimmune disorder | |
| CA3014071C (en) | Methods for the use of 5'-adenosine diphosphate ribose (adpr) | |
| US20160095861A1 (en) | Ophthalmic ointments comprising valganciclovir hydrochloride for treating infective eye diseases | |
| US20140213605A1 (en) | Methods for treating eye disorders using opioid receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W019 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: OFFICE LETTER Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W019 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: OFFICE LETTER Effective date: 20240703 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250205 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260205 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260209 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260209 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260211 |